University of Colorado, Denver
Organization-level profile for a sponsor, institution, collaborator, or mixed-role entity. These profiles are separated from the primary industry company index when appropriate.
Programs by Stage
Trial / Program Status
Modality Mix
Indication Coverage
Program Types
Population Tags
Strong-Evidence Records
0 recordsChecked Records With Caveats
3 checked · 0 open checksAcademic Phase 2 study treating biochemically confirmed Smith-Lemli-Opitz syndrome with cholesterol supplementation plus antioxidant medication, while monitoring sterol biochemistry and serial clinical measures including brainstem audiometry. Hearing loss is part of the syndromic phenotype and monitoring plan, but the cholesterol and antioxidant components are one systemic SLOS treatment protocol rather than separate hearing-loss pipeline programs.
Clemastine fumarate combined with proprietary engineered sound stimulation, intended to drive remyelination of activated central auditory pathways for age-related central auditory processing disorder/hearing-in-noise deficits.
Withdrawn randomized Phase 2 academic study comparing hearing outcomes and side effects for oral dexamethasone versus oral prednisone in unilateral sudden sensorineural hearing loss.